# Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies

> **NCT01527045** · PHASE2 · COMPLETED · sponsor: **Fred Hutchinson Cancer Center** · enrollment: 47 (actual)

## Conditions studied

- Aggressive Non-Hodgkin Lymphoma
- Blasts Under 5 Percent of Bone Marrow Nucleated Cells
- Chronic Lymphocytic Leukemia
- Loss of Chromosome 17p
- Myelodysplastic/Myeloproliferative Neoplasm
- Non-Hodgkin Lymphoma
- Prolymphocytic Leukemia
- Recurrent Adult Acute Lymphoblastic Leukemia
- Recurrent Adult Acute Myeloid Leukemia
- Recurrent Aggressive Adult Non-Hodgkin Lymphoma
- Recurrent Childhood Acute Lymphoblastic Leukemia
- Recurrent Childhood Acute Myeloid Leukemia
- Recurrent Chronic Lymphocytic Leukemia
- Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Recurrent Diffuse Large B-Cell Lymphoma
- Recurrent Hodgkin Lymphoma
- Recurrent Mantle Cell Lymphoma
- Recurrent Non-Hodgkin Lymphoma
- Recurrent Plasma Cell Myeloma
- Recurrent Small Lymphocytic Lymphoma
- Waldenstrom Macroglobulinemia

## Interventions

- **DRUG:** Atorvastatin Calcium
- **DRUG:** Cyclosporine
- **DRUG:** Fludarabine Phosphate
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Mycophenolate Mofetil
- **PROCEDURE:** Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation
- **PROCEDURE:** Peripheral Blood Stem Cell Transplantation
- **RADIATION:** Total-Body Irradiation

## Key facts

- **NCT ID:** NCT01527045
- **Lead sponsor:** Fred Hutchinson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-09-25
- **Primary completion:** 2018-10
- **Final completion:** 2019-04
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2020-01-02

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01527045

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01527045, "Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01527045. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*